摘要
目的探讨新型CpG佐剂BW006协同乙型肝炎病毒表面抗原(HBsAg)对小鼠B、T淋巴细胞活化的影响。方法以BW006和(或)HBsAg体外刺激小鼠脾单个核细胞,检测B细胞膜表面分子CD80、CD86和T细胞早期活化分子CD69的表达水平。小鼠免疫BW006和(或)HBsAg后24h取脾,无菌分离单个核细胞,检测CD80、CD86和CD69的表达水平。结果 40μgHBsAg+5μg BW006体外刺激24h时,B细胞CD80、CD86阳性率显著高于对照组(27.36%±1.77%vs 10.41%±0.72%;98.92%±0.09%vs 74.85%±5.13%,P均<0.01),T细胞CD69阳性率显著高于对照组(12.47%±3.31%vs 7.15%±1.37%,P<0.01)。4μg HBsAg+20μg BW006联合免疫后,小鼠脾B细胞CD80的阳性率显著高于BW006免疫组(12.26%±2.33%vs 9.80%±1.17%P<0.05)和生理盐水免疫组(12.26%±2.33%vs 8.50%±1.34%,P<0.05),CD86阳性率显著高于生理盐水免疫组(63.84%±1.48%vs 56.69%±1.33%,P<0.05),T细胞CD69表达阳性率显著高于BW006组(33.97%±2.17%vs 31.32%±2.78%,P<0.05)和生理盐水组(33.97%±2.17%vs 27.77%±2.51%,P<0.05)。结论 BW006佐剂能有效辅助HBsAg活化B和T细胞,上调B细胞表面协同刺激分子CD80、CD86及T细胞早期活化分子CD69的表达。
Objective To explore the influence of a new type CpG adjuvant - BW006 on immune response of B and T lymphocytes stimulated by hepatitis B surface antigen （HBsAg）. Methods Mononuclear cells were isolated from mice spleen and stimulated in vitro by BW006 and（or） HBsAg. Expression levels of surface molecules of B cell （CD80, CD86） and early activating molecule （CD69） of T cell were detected by flow cytometer. BALB/c mice were immunized in vivo by BW006 and/or HBsAg and expression levels of CD80, CD86 and CD69 on mononuclear cells were detected by flow cytometer. Results Average positive rates of CD80 and CD86 on B cell and CD69 on T cell from mice stimulated in vitro by 40lμg HBsAg ＋ 5pμg BW006 were significantly higher than those from control group （P 〈 0.01 ）. For mice immunized in vivo by 4lμg HBsAg ＋ 20/~g BW006, expression levels of CD80 and CD86 on B cell were significantly higher than those from BW006 group （ P 〈 0.05 ） , and expression level of CD69 on T cell were significantly higher than those from BW006 group and HBsAg group （ P 〈0.05） . Conclusion BW006 provides efficient help to HBsAg in the activation of B and T cells by upregulating the expression of co-stimulating molecules of B cell （ CD80, CD86） and early activating molecule （CD69） of T cell.
出处
《医学研究杂志》
2011年第11期27-32,共6页
Journal of Medical Research
基金
国家科技重大专项艾滋病和病毒性肝炎等重大传染病防治基金资助项目(2009ZX10004-802)
